Stoke Therapeutics

STOK on Nasdaq. Pharmaceutical preparations. Market value $1.7bn.

Watch this stockFree. We tell you when something changes.

Price checks use the past 12 months to September 2026. Quality checks use five annual reports, the latest for the year to December 2025.

Should I look at this?

Not a fit for our list right now

See Health care stocks that passed both tests

This is not advice. Check the numbers below.

Compare with another stock

Cash yield
past 12 months to September 2026
-12.3%low

For every $100 of what the whole company costs, it produced $-12.30 of spare cash in the past 12 months. A savings account pays about $4.

Price to profit
past 12 months to September 2026
n/a

The filings do not give us enough to work this out.

Return on capital
five annual reports to December 2025
-86.3%five-year median

Each dollar kept in the business earns -86 cents a year. Above 10 is good.

Quality score: 44 of 100. Price score: 0 of 100. Our list needs 70 on quality and 60 on price.

$26.81 a share, 22% above its 1-year low

Over the past year the price has ranged from $22.05 to $40.22.

Pays no dividend

Prices from Friday’s close (20 November).

Five years of cash, in billions

-0.1
-0.0
-0.1
-0.1
0.0
-0.2
2021202220232024202512 monthsto Sep '26

Spare cash swings from quarter to quarter here: a shortfall of $216 million in the past 12 months, $45 million in the year to December 2025.

Revenue
n/a$12m$9m$37m$184m
Operating margin
n/a-841.2%-1307.2%-277.3%-11.2%
Debt to equity
0.000.000.000.000.00
Shares outstanding
0.04bn0.04bn0.05bn0.06bn0.07bn

Health checks

  • Free cash flow positive1 of 5 years
  • Accounting looks honest (Beneish)Not enough data
  • Financial strength (Piotroski)3 of 8 checks we could run
  • Profit backed by cash (accruals)No
  • Debt0.00× equity
  • Revenue growth, five yearsStrong, 145.8% a year
  • Buying back its own sharesNo, 66% more shares since 2021

The quarter to September 2026

How the business did, compared with the same quarter a year earlier.

  • Sales: $11 million last quarter, about the same as a year ago.
  • A loss of $74 million, compared with a loss of $38 million a year ago.
  • It loses 913 cents on each $1 of sales, after keeping 13 cents a year earlier.
  • Over the past 12 months it spent $216 million more cash than it brought in. A year earlier it had $52 million spare.
  • 17% more shares than a year ago. Each share owns a bit less of the company.
  • It has $107 million more cash than debt, up from $83 million a year ago.
  • Sales grew on a year ago in 1 of the last 4 quarters.
Sales by quarter
Sales by quarter
Quarter toAmount
December 2024$23m
March 2025$159m
June 2025$14m
September 2025$11m
December 2025$1m
March 2026$6m
June 2026$9m
September 2026$11m
Profit by quarter
Profit by quarter
Quarter toAmount
December 2024-$10m
March 2025$113m
June 2025-$23m
September 2025-$38m
December 2025-$58m
March 2026-$50m
June 2026-$62m
September 2026-$74m

From the company's quarterly reports to the SEC.

Dates

Next results (estimated)
n/a
Last annual report (10-K)
16 March 2026
Next quarterly (estimated, 10-Q)
2 February 2027

Who owns it

1 long-term investor we follow owns it, unchanged from 1 last quarter. 198 funds in all.

Jun '25
Dec '25
Jun '26
Largest holders overall

From 13F filings for the quarter ended 30 June 2026.

Big holders and activists

12 investors own more than 5%.

  • Montrago Trustees Limited
    Passive investor
    at least 13.0%
    (filed with 2 related holders)
    Since 23 December 2024
    What they said

    Item 4 is hereby amended and supplemented by adding the following: On December 23, 2024, Blue Horizon sold 2,000,000 Shares of the Issuer in an open market transaction at a price of $11.50 per share.

    Read the filing
  • Roderick Wong, M.D.
    Passive investor
    10.0%
    Since 31 December 2024
  • RTW Investments, LP
    Passive investor
    at least 9.9%0.0 pts
    (filed with 1 related holder)
    Since 30 September 2026
  • FMR LLC
    Passive investor
    at least 7.5%−1.0 pts
    (filed with 1 related holder)
    Since 30 September 2026
  • at least 7.3%+2.1 pts
    (filed with 3 related holders)
    Since 30 September 2026
  • BlackRock, Inc.
    Passive investor
    6.8%+1.0 pts
    Since 30 September 2025
  • Redmile Group, LLC
    Passive investor
    at least 6.7%−1.3 pts
    (filed with 2 related holders)
    Since 31 March 2026
  • at least 6.5%−1.6 pts
    (filed with 1 related holder)
    Since 30 June 2026
  • BVF PARTNERS L P/IL
    Passive investor
    at least 5.6%
    (filed with 9 related holders)
    Since 23 September 2026
  • Morgan Stanley
    Passive investor
    at least 4.9%−1.6 pts
    (filed with 1 related holder)
    Since 30 September 2026
  • Baker Bros. Advisors LP
    Passive investor
    at least 4.7%−1.1 pts
    (filed with 3 related holders)
    Since 30 September 2026
  • Skorpios Trust
    Passive investor
    at least 4.1%−1.9 pts
    (filed with 3 related holders)
    Since 22 August 2025
    What they said

    Item 4 is hereby amended and supplemented by adding the following: On August 22, 2025, Blue Horizon sold 1,000,000 Shares of the Issuer in an open market transaction at a price of $18.50 per share.

    Read the filing
  • Sold down below 5%
    Since 30 June 2026
  • BlackRock Portfolio Management LLC
    Passive investor
    Sold down below 5%
    Since 30 June 2025
  • The Vanguard Group
    Passive investor
    Sold down below 5%
    Since 13 March 2026
  • Cowen Financial Products LLC
    Passive investor
    Sold down below 5%
    Since 30 September 2025

From Schedule 13D and 13G filings: anyone owning more than 5% must file one.

What insiders did

No insider bought shares on the open market in the last 12 months. 8 sold $8m, $6m of it under preset trading plans.

  • Ticho Barry
    CHIEF MEDICAL OFFICER
    Sold
    under a preset trading plan
    Date
    2 November 2026
    Shares
    7,195
    Price
    $26.39
    Value
    $189,912
  • Allan Jonathan
    GENERAL COUNSEL & CORP SEC
    Sold
    under a preset trading plan
    Date
    2 October 2026
    Shares
    627
    Price
    $26.33
    Value
    $16,509
  • Ticho Barry
    CHIEF MEDICAL OFFICER
    Sold
    under a preset trading plan
    Date
    1 October 2026
    Shares
    1,051
    Price
    $26.16
    Value
    $27,494
  • Ticho Barry
    CHIEF MEDICAL OFFICER
    Sold
    under a preset trading plan
    Date
    1 September 2026
    Shares
    5,545
    Price
    $30.67
    Value
    $170,061
  • Allan Jonathan
    GENERAL COUNSEL & CORP SEC
    Sold
    Date
    18 August 2026
    Shares
    2,861
    Price
    $32.03
    Value
    $91,639
  • Ticho Barry
    CHIEF MEDICAL OFFICER
    Sold
    Date
    18 August 2026
    Shares
    4,767
    Price
    $32.03
    Value
    $152,690
  • Kaye Edward M. MD
    Director
    Sold
    Date
    18 August 2026
    Shares
    12,567
    Price
    $32.03
    Value
    $402,528
  • Ticho Barry
    CHIEF MEDICAL OFFICER
    Sold
    under a preset trading plan
    Date
    3 August 2026
    Shares
    7,176
    Price
    $29.04
    Value
    $208,385
  • Ticho Barry
    CHIEF MEDICAL OFFICER
    Sold
    under a preset trading plan
    Date
    1 July 2026
    Shares
    7,228
    Price
    $32.66
    Value
    $236,068
  • Allan Jonathan
    GENERAL COUNSEL & CORP SEC
    Sold
    under a preset trading plan
    Date
    16 June 2026
    Shares
    1,457
    Price
    $29.95
    Value
    $43,637

From Form 4 filings: insiders must report trades in their own company's shares within two days.

Warning signs in its filings

Problems the company itself reported to the SEC, in its own words.

None of the serious warning signs we check for were found. 1 thing worth knowing.

We look for five warning signs: doubt it can keep going, weak checks on its own accounts, a notice that its past accounts can't be relied on, a change of auditor, and one customer bringing in a big share of sales. We don't check lawsuits, investigations or debt yet.

We checked the auditor's report, internal controls, restatement notices, auditor changes and big customers in the 10-K filed 16 Mar 2026, plus the 10-Q filed 3 Nov 2026 and 9 later 8-Ks.

  • Changed auditor

    Worth knowing

    The company changed its auditor (the firm that checks its books) in the last two years.

    “On March 23, 2026, the Audit Committee (the “Audit Committee”) of the Board of Directors of Stoke Therapeutics, Inc. (the “Company”) dismissed KPMG LLP (“KPMG”) as the Company’s independent registered public accounting firm.”

    From an 8-K filed 27 March 2026: Change of auditor. Read it in the filing

A 10-K is the yearly report every US company files with the SEC. An 8-K is a short notice of a big event.

What could go wrong

Cheap for a reason is the question the numbers cannot answer.

Whether the price already reflects the risks is what the deep dive is for.

The deep dive

Everything above is arithmetic on public filings. The deep dive reads the last ten years of annual reports, the proxy statements, and the earnings calls, then argues the case the way Buffett, Klarman, and Hohn would, and checks every claim against the source.

  • What the business is worth, as a range, and the margin of safety at today’s price
  • Prices to start buying, buy, and buy hard
  • The three things that would make this a mistake
  • Every number footnoted to the filing it came from
Create a free account to run it

Your first deep dive is free.

What a finished deep dive looks like

Not advice. Numbers on this page come from SEC filings and are updated each night; prices are updated again after the US market closes. The five-year figures are rounded.